S65487 and azacitidine
Phase 2Small molecule
Institut de Recherches Internationales ServierS65487 and azacitidine is one of 52 small molecule programs targeting Acute Myeloid Leukemia. It is currently in Phase 2.
1
Indications
2
Total Trials
1
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
255 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Xospata
AstellasPhase 3
Fludara
SanofiPhase 3
Cerubidine
EEastern Cooperative Oncology Group
Phase 3
Vepesid
AAvyxa
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Vanflyta
Daiichi SankyoPhase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Nexavar
BayerPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Lymphocytic Leukemia1 trial
Acute Myeloid Leukemia1 trial
Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia
Active, not recruiting·Institut de Recherches Internationales Servier·Phase 1/2·NCT04742101·57 enrolled
Institut de Recherches Internationales Servier·Phase 1/2·NCT04742101·57 enrolledSources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for S65487 and azacitidine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details